News for Telo Genomics Corp. (TDSGF)

Telo Genomics (TSXV: TELO, OTCQB: TDSGF) announced ASCO 2025 has accepted its MRD validation data for multiple myeloma. The company is developing two pr

Telo Genomics Presents New Performance Data for Its Smoldering Myeloma Prognostic Test

PALM BEACH, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Recent reports show that the Multiple myeloma Diagnostic market will...

Telo Genomics Corp. , , an emerging molecular testing platform provider leveraging the power of telomeres, is excited to announce the initiation of their Physician Experience Program - SMART . ...

Toronto, Ontario - July 13, 2022 (Newsfile Corp.) (Investorideas.com Newswire) Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "TELO") is plea...

Telo Genomics Corp. is pleased to announce that it is participating in the 18th International Myeloma Society Workshop 2021 taking place in Vienna, Austria between September 8th - 11th. Telo... | September 9, 2021

Telo Genomics Corp. is pleased to announce that the Company has entered into an agreement with the clinical laboratory veteran Mark Stene, Founder & President of MyClinLab® LLC, Austin,... | August 9, 2021

VANCOUVER, BC, July 8, 2021 /CNW/ - TSX VENTURE COMPANIESA.I.S. RESOURCES LIMITED ('AIS')BULLETIN TYPE:  CUSIP ChangeBULLETIN DATE:  July 8, 2021T...

Telo Genomics Corp. is pleased to announce a non-brokered private placement of units at a price of $0.50 per Unit for gross proceeds of $1,500,000 . Each Unit will consist of one common share of... | June 18, 2021